AbbVie beats by $0.02, reports revs in-line; guides FY17 EPS in-line
- Reports Q2 (Jun) earnings of $1.42 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $1.40; revenues rose 7.6% year/year to $6.94 bln vs the $6.93 bln Capital IQ Consensus
- Global HUMIRA sales increased 13.7% on a reported basis, or 14.9% operationally, excluding a 1.2% unfavorable impact from foreign exchange. In the U.S., HUMIRA sales grew 18.0% in the quarter. Internationally, HUMIRA sales grew 9.1%, excluding a 3.6% unfavorable impact from foreign exchange.
- Second-quarter global IMBRUVICA net revenues were $626 million, with U.S. sales of $528 million and international profit sharing of $98 million for the quarter, reflecting growth of 42.6%.
- Co issues in-line guidance for FY17, sees EPS of $5.44-5.54, excluding non-recurring items, vs. $5.53 Capital IQ Consensus Estimate.